Nexentis Technologies (NXTS) Stock Price, Financials & Analysis

Key Stats

Market Cap2.04 Mn

P/E-0.13

FCF (Yr)-3.82 Mn

ROA (Yr)-32.13

EV to EBIT2.15

Net Income (Yr)-4.16 Mn

Enterprise Value-23.39 Mn

Add ratio to table…

About

Nexentis Technologies Inc. is a Nevada incorporated company that focuses on sustainable operations through two core business areas. The first area is oncology biotechnology conducted by its wholly owned subsidiary MitoCareX Bio Ltd which develops drug candidates that target mitochondrial carrier proteins for cancer and inflammatory metabolic diseases. The second area is solar energy project development carried out by its subsidiary Solterra Renewable Energy Ltd which…

Nexentis generates revenue from several sources. MitoCareX plans to earn income through licensing of its MITOLINE platform milestone payments and royalties on future approved therapeutics. Solterra derives revenue from the sale of solar energy projects to third parties at various stages of development. Additionally the company provides non exclusive advisory support and collaboration services to Voice Assist under a services agreement receiving deferred cash royalty consideration and a share of any Ecolab gross proceeds.

The company operates through the following segments.

MitoCareX Bio Ltd.: a drug discovery company focused on developing therapeutics targeting the mitochondrial carrier family for cancer and inflammatory metabolic diseases using its proprietary MITOLINE algorithm and computational platform to identify and advance small molecule compounds.
Solterra Renewable Energy Ltd.: a solar energy project developer that engages in the identification development and sale of renewable energy projects in Europe primarily in Italy Poland and Germany with a business model centered on selling projects at various stages of development to third parties.

Nexentis holds a niche position in the biotechnology sector where MitoCareX differentiates itself through its MITOLINE algorithm that enables reliable three dimensional modeling of mitochondrial carrier proteins a capability not widely available among competitors. In the solar energy space Solterra operates as a project developer in markets where large integrated utilities and specialized local firms compete for opportunities but the company focuses on early stage project identification and sale to third parties allowing it to leverage technical expertise without bearing long term construction and operation risks.

MitoCareX sells its platform access and potential drug candidates to pharmaceutical and biotechnology firms seeking novel targets for cancer and metabolic diseases. Solterra sells its solar projects to utilities independent power producers and other renewable energy investors. The company also provides advisory services to Voice Assist a publicly traded Nevada corporation.

How Nexentis Technologies ranks

Ranked against the 671 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.02xMedian 17.8x 2^nd
P/FCFNegative free cash flow −0.09xMedian 21.0x 4^th
P/Operating cash flowNegative operating cash flow −0.09xMedian 16.8x 4^th
P/S —Median 8.14x No data —
P/B 0.21xMedian 2.02x 94^th
P/Tangible bookNegative tangible equity −0.17xMedian 2.24x Not meaningful —
EV/EBITDANet cash exceeds market value 0.76xMedian 15.7x Not meaningful —
EV/EBITNet cash exceeds market value 0.74xMedian 20.9x Not meaningful —
EV/Revenue —Median 5.92x No data —
EV/FCFNet cash exceeds market value 1.79xMedian 22.0x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 1.82xMedian 18.3x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.36 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 11.0% No data —
Revenue CAGR (3Y) —Median 10.4% No data —
Gross profit growth (1Y) —Median 11.8% No data —
Gross profit CAGR (3Y) —Median 12.3% No data —
Operating income growth (1Y) −127%Median −1.6% 9^th
Operating income CAGR (3Y) −23.5%Median 1.4% 24^th
Net income growth (1Y) −70.1%Median −3.3% 23^rd
Net income CAGR (3Y) −42.2%Median −0.1% 13^th
EPS growth (1Y) −667%Median 22.4% 3^rd
EPS CAGR (3Y) −52.0%Median 25.9% 7^th
Operating cash flow growth (1Y) −62.8%Median −0.4% 17^th
Operating cash flow CAGR (3Y) −0.4%Median 2.1% 47^th
Free cash flow growth (1Y) −65.5%Median −0.1% 17^th
Free cash flow CAGR (3Y) −0.7%Median 2.5% 45^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 74.2% No data —
EBITDA margin —Median −214% No data —
Operating margin —Median −213% No data —
Pretax margin —Median −205% No data —
Net margin —Median −196% No data —
FCF margin —Median −181% No data —
Operating cash flow margin —Median −175% No data —
Return on equity −219%Median −54.7% 13^th
Return on assets −92.0%Median −41.1% 24^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −73.7%Median −47.8% 34^th
Asset turnover —Median 0.18x No data —
Cash conversion (OCF / net income)Net income is not positive 0.27xMedian 1.14x Not meaningful —
Stock comp / revenue —Median 29.2% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 2.3%Median 20.0% 85^th
Debt / equity 0.22xMedian 0.27x 53^rd
Net debt / EBITDAEBITDA is not positive 0.80xMedian 1.22x Not meaningful —
Debt / FCFFree cash flow is not positive −0.09xMedian 3.65x Not meaningful —
Liabilities / assets 89.8%Median 32.3% 19^th
Equity / assets 10.2%Median 67.7% 19^th
Interest coverage —Median −10.0x No data —
Current ratio 3.72xMedian 4.37x 45^th
Quick ratio 3.18xMedian 3.65x 46^th
Cash ratio 3.18xMedian 3.35x 48^th
Altman Z-score —Median −0.80 No data —

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.5% No dividend —
Net buyback yieldAbove 100% of market value −2,491%Median −3.5% Not meaningful —
Shareholder yieldAbove 100% of market value −2,491%Median −2.4% Not meaningful —
Payout ratio (earnings) —Median 79.0% No dividend —
Payout ratio (FCF) —Median 61.8% No dividend —
Dividend growth (1Y) —Median 2.9% No dividend —
Dividend CAGR (3Y) —Median 3.3% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,261.99 Bn	45.76	14.60	49.50 Bn
2	JNJ	Johnson & Johnson	678.93 Bn	42.18	6.83	44.65 Bn
3	ABBV	AbbVie Inc.	518.29 Bn	50.12	7.85	80.90 Bn
4	MRK	Merck & Co., Inc.	365.98 Bn	149.20	5.43	53.78 Bn
5	NVS	Novartis Ag	316.85 Bn	17.91	5.08	-
6	AZN	Astrazeneca Plc	293.40 Bn	26.60	4.94	-11.96 Bn
7	AMGN	Amgen Inc	251.78 Bn	26.81	6.47	54.01 Bn
8	NXTS	Nexentis Technologies Inc.	0.00 Bn	-0.13	-	0.00 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,261.99 Bn

45.76

14.60

49.50 Bn

JNJ

Johnson & Johnson

678.93 Bn

42.18

6.83

44.65 Bn

ABBV

AbbVie Inc.

518.29 Bn

50.12

7.85

80.90 Bn

MRK

Merck & Co., Inc.

365.98 Bn

149.20

5.43

53.78 Bn

NVS

Novartis Ag

316.85 Bn

17.91

5.08

AZN

Astrazeneca Plc

293.40 Bn

26.60

4.94

-11.96 Bn

AMGN

Amgen Inc

251.78 Bn

26.81

6.47

54.01 Bn

NXTS

Nexentis Technologies Inc.

0.00 Bn

-0.13

0.00 Bn

Nexentis Technologies NXTS

About

Geographical Breakdown of Revenue (2024)

Consolidation Items Breakdown of Revenue (2024)

How Nexentis Technologies ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Nexentis Technologies NXTS

About

Geographical Breakdown of Revenue (2024)

Consolidation Items Breakdown of Revenue (2024)

How Nexentis Technologies ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password